slides · global inventory
Diagram
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 23,622
Current window 16,261-16,290
Pages 788
Rows per page 30
Component
16,261-16,290 of 23,622
07
The slide uses a timeline to show the shift from non-luxury to luxury, and donut charts to illustrate the change in revenue composition.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Situation & ContextLoop · Aha Moment1 hit
10
The slide uses a split-screen layout comparing Kering Eyewear (historical revenue growth) and Kering Beauté (timeline of launch and acquisition).Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Aha Moment1 hit
34
The diagram is a circular process model showing how different business stages contribute to circularity.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
36
The slide uses a hub-and-spoke style layout to categorize sustainability achievements.Kering | Investor Presentation Deck | 63 slides · Kering
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Cost Of Inaction1 hit
08
Includes a biological pathway diagram and a specific 'Degrader Advantage' callout box.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
09
Includes a mechanism of action diagram, a market data table, and a comparison of current therapy limitations.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
22
Includes a table of prevalence/incidence for various indications and a diagram of the JAK-STAT signaling pathway.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
24
The slide uses a process flow diagram to illustrate the dose escalation (0.05 to 0.40 mg/kg) leading to MTD/RP2D expansion into four specific patient cohorts.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
32
Includes a waterfall plot of cell line dependency and a biological process diagram showing the MDM2-p53 feedback loop.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
35
Includes a visual representation of the dose escalation study design and a detailed table of patient baseline characteristics.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide combines a biological mechanism diagram with clinical trial data (table and line chart) to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 41 slides · Kymera
Pitch deck Investor relations 1 hit
08
The slide uses a visual comparison of protein structures to explain the mechanism of action.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide outlines the methodology for a clinical trial, specifically focusing on the 28-day treatment schedule and cohort details.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
25
The slide outlines the clinical trial methodology for a drug candidate in Friedreich's Ataxia (FA) patients.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
26
The slide details the dosing schedule (13 days) and specific sampling days for buccal cells, skin, and platelets across three dose cohorts (25mg, 50mg, 100mg).Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
33
The slide outlines a 28-day treatment schedule with specific administration days highlighted in green.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
09
The slide uses a grid-based layout to organize clinical trials by stage and therapeutic focus.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
04
Uses a hub-and-spoke diagram to center the company's focus on 'Building Owners'.Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations 1 hit
10
The slide uses a process-flow diagram to list markets, followed by a three-pillar framework explaining the strategic value of these segments.Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The slide uses a three-column layout to represent the pillars of the business strategy.Limbach Holdings | Investor Presentation Deck | 28 slides · Limbach
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
The slide uses a hub-and-spoke diagram to illustrate the ecosystem surrounding the core vehicle offering.Lion Electric | Investor Presentation Deck | 30 slides · Lion Electric
Pitch deck Investor relations Beat · SolutionLoop · Voice Of Customer1 hit
04
The diagram uses a hub-and-spoke style layout with vehicles at the center.Lion Electric | Results Presentation Deck | 21 slides · Lion Electric
Conference presentation Investor relations Beat · Problem1 hit
07
The slide uses a timeline to show strategic milestones and pie charts to show revenue composition changes over time.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations 1 hit
36
The slide uses a radial/fan-like diagram to organize strategic components around a central 'Customers & Markets' hub.LKQ | Results Presentation Deck | 62 slides · LKQ
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The slide outlines a multi-part clinical trial process (Part A, Part B, and Expansion) for NSCLC 2L patients.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Traction1 hit
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
31
The slide outlines a clinical trial process flow from initial baskets through immune activation to a pivotal phase.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
15
The slide highlights the cost efficiency of the internal management structure and provides financial snapshots of the parent BDC and two SBIC funds.Main Street Capital | Investor Presentation Deck | 49 slides · Main Street Capital Corporation
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit